The U.S. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market is set for robust growth over the next decade. Valued at USD 214.00 million in 2024, the market is projected to grow at a compound annual growth rate (CAGR) of 7.50% from 2025 to 2034, reaching an estimated USD 440.23 million by the end of the forecast period. This growth is largely fueled by...